- Home
- ELVN vs ATAI Comparison
ELVN vs ATAI Comparison
Compare ELVN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- ATAI
- Stock Information
- Founded
- ELVN 2016
- ATAI 2018
- Country
- ELVN United States
- ATAI Netherlands
- Employees
- ELVN N/A
- ATAI N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- ATAI Health Care
- Exchange
- ELVN Nasdaq
- ATAI Nasdaq
- Market Cap
- ELVN 1.2B
- ATAI 1.1B
- IPO Year
- ELVN 2020
- ATAI 2021
- Fundamental
- Price
- ELVN $20.90
- ATAI $5.53
- Analyst Decision
- ELVN Strong Buy
- ATAI Strong Buy
- Analyst Count
- ELVN 5
- ATAI 4
- Target Price
- ELVN $41.20
- ATAI $13.75
- AVG Volume (30 Days)
- ELVN 563.5K
- ATAI 5.8M
- Earning Date
- ELVN 11-12-2025
- ATAI 11-12-2025
- Dividend Yield
- ELVN N/A
- ATAI N/A
- EPS Growth
- ELVN N/A
- ATAI N/A
- EPS
- ELVN N/A
- ATAI N/A
- Revenue
- ELVN N/A
- ATAI $2,309,000.00
- Revenue This Year
- ELVN N/A
- ATAI $707.47
- Revenue Next Year
- ELVN $20.05
- ATAI N/A
- P/E Ratio
- ELVN N/A
- ATAI N/A
- Revenue Growth
- ELVN N/A
- ATAI 510.85
- 52 Week Low
- ELVN $13.30
- ATAI $1.03
- 52 Week High
- ELVN $30.03
- ATAI $5.97
- Technical
- Relative Strength Index (RSI)
- ELVN 51.84
- ATAI 62.56
- Support Level
- ELVN $19.02
- ATAI $4.99
- Resistance Level
- ELVN $20.66
- ATAI $5.68
- Average True Range (ATR)
- ELVN 1.00
- ATAI 0.36
- MACD
- ELVN 0.09
- ATAI -0.01
- Stochastic Oscillator
- ELVN 69.85
- ATAI 54.62
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.